Current Report · Items 9.01 · 8-K/A

Collegium Pharmaceutical, Inc.

COLLNASDAQEQUITYCurrent

Financial Statements and Exhibits

Filed Jun 30, 2026Accepted Jun 30, 2026, 4:05 PM EDTCIK 1267565Accession 0001104659-26-079323

Company context

Collegium Pharmaceutical is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. Collegium has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions.

Current securities

COLLNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 9.01Item 9.01 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (a) Financial Statements of the Business Acquired. The audited financial statements of Corium as of and for the years ended December 31, 2025 and 2024, including the related notes thereto, are filed herewith as Exhibit 99.1 and incorporated herein by reference. The unaudited financial statements of Corium as of March 31, 2026 and for the three months ended March 31, 2026 and 2025, including the related notes thereto, are filed herewith as Exhibit 99.2 and incorporated herein by reference. (b) Pro Forma Financial Information. The unaudited pro forma condensed combined balance sheet of the Company as of March 31, 2026 and the unaudited pro forma condensed combined statements of operations of the Company for the three months ended March 31, 2026 and the year ended December 31, 2025, including the related notes thereto, giving effect to the Acquisition are filed herewith as Exhibit 99.3 and incorporated herein by reference. (c) Exhibits Exhibit No. Description ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 23.1 Consent of Grant Thornton LLP, Corium Therapeutics Holdings, LLC’s independent auditor. 23.2 Consent of Ernst & Young LLP, Corium Therapeutics Holdings, LLC’s independent auditor. 99.1 Audited financial statements of Corium Therapeutics Holdings, LLC as of and for the years ended December 31, 2025 and 2024, including the related notes thereto. 99.2 Unaudited condensed financial statements of Corium Therapeutics Holdings, LLC as of March 31, 2026 and for the three months ended March 31, 2026 and 2025, including the related notes thereto. 99.3 Unaudited pro forma condensed combined balance sheet of the Company as of March 31, 2026, and unaudited pro forma condensed combined statements of operations of the Company for the three months ended March 31, 2026 and the year ended December 31, 2025, including the related notes thereto. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

Filed exhibits (2)

EX-99.1 (by filename) tm2618928d1_ex99-1.htm

Exhibit 99.1 Consolidated Financial Statements and Report of Independent Certified Public Accountants Corium Therapeutics Holdings, LLC December 31, 2025 and 2024 Contents Page Report of Independent Certified 3 Public Accountants Report of Independent Auditors 6 Consolidated Financial Statements Consolidated balance sheets 9 Consolidated statements of 10 operations and comprehensive loss Consolidated statements of 11 changes in members’ capital Consolidated statements of 12 cash flows Notes to the consolidated financial 13 statements GRANT THORNTON LLP REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS 53 State Street, 16th Floor Boston, MA 02109 D +1 617 723 7900 Board of Directors …

Open exhibit ↗

EX-99.2 (by filename) tm2618928d1_ex99-2.htm

Exhibit 99.2 Condensed Consolidated Financial Statements Corium Therapeutics Holdings, LLC For the quarterly period ended March 31, 2026 Contents Page Condensed Consolidated Financial Statements Unaudited condensed consolidated 3 balance sheets Unaudited condensed consolidated 4 statements of operations and comprehensive loss Unaudited condensed consolidated 5 statements of changes in members’ capital Unaudited condensed consolidated 6 statements of cash flows Notes to the condensed 7 consolidated financial statements Corium Therapeutics Holdings, LLC UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In Thousands) March 31, December 31, 2026 2025 ───────────────────…